| 391 LOWER ESOPHACEAL SF<br>INFANTS. Dean L. An<br>Charles L. Paxson,  | itonson, Jon A | Vanderhoof, | and    |
|---|----------------|-------------|--------|
| Omaha, Neb. (Spon.  |                |             | ,      |
| Nasojejunal feedings are frequently advocated for ill preterm   |                |             |        |
| infants on the basis of lower esophageal sphincter (LES) in comp-   |                |             |        |
| etence. We previously evaluated LES pressures in healthy term   |                |             |        |
| infants and found them to be indicative of sphincter competence.  |                |             |        |
| We have now measured LES pressures in 7 ill preterm infants   |                |             |        |
| receiving respiratory assistance. Pressure recordings were ob-  |                |             |        |
| tained using a single lumen side opening perfused catheter, and   |                |             |        |
| compared with pressures from healthy term and preterm infants   |                |             |        |
| (see table). The groups differed in gestational age (GA), and   |                |             |        |
| postnatal age (PA) but LES pressures were unaffected by these two   |                |             |        |
| variables. Even the smallest infant studied (720gm, pH 7.20)  |                |             |        |
| exhibited normal LES pressure (40 mmHg). Subsequent to studies,<br>all infants were fed by continuous drip gastric lavage without |                |             |        |
| any clinical evidence of regurgitation or aspiration.   |                |             |        |
| Infants   | PA (da.)       | LES(mmHg)   | GA(wk) |
| Healthy term (n=10)   | 2              | 39.4        | 40     |
| Healthy preterm (n=10)  | 15             | 39.4        | 35     |
| Ill Preterm (n=7)   | 13             | 35.0        | 33     |
| Our data indicates that the LES is competent at an early  |                |             |        |
| developmental age. The use of nasojejunal instead of nasogastric  |                |             |        |
| eedings can not be justified on the basis of suspected LES  |                |             |        |
| incompetence.   |                |             |        |

THE EFFECT OF REYE'S SYNDROME SERUM ON MITOCHONDRIAL 392 RESPIRATION IN VITRO. June R. Aprille and Gregory K. Asimakis (Spon by John D. Crawford) Tufts Univ., Dept. Biology, Medford. MA, Harvard Medical School, Dept. Pediat. nd Mass. General Hosp., Children's Service, Boston, MA Recently we showed that serum from Reve's Syndrome (RS) tients has an effect on the respiratory function and morphology of isolated rat liver mitochondria (mito.) suggesting the exist ence of a pathogenic serum factor. We now report further investi-gation into the biochemical mechanism of action of the serum actor. In vitro respiratory rates of isolated rat liver mito. ere assessed polarographically as described previously (Science 97:908, 1977). State 4 respiration was markedly increased in he presence of RS serum as compared to control serum. To distinuish among several mechanisms for the increase in state 4 res-iration, inhibitors of specific mito. functions were tested as ossible antagonists of the RS effect. The inhibitors used were: ligomycin, an inhibitor of mito. ATPase, ruthenium red, which locks mito. Ca<sup>++</sup> transport; and three site-specific e<sup>-</sup> transport chain inhibitors: rotenone (site I), antimycin A (site II), KCN (site III). In each case RS serum was added to the assay in the presence of inhibitor to see if the usual stimulation of respira-tory rate could be blocked. Of the inhibitors thus tested only KCN abolished the effect of RS serum. We concluded that the put ative serum factor stimulated respiration by directly or indir-ectly reducing components of the e<sup>-</sup> transport chain at a point eyond phosphorylation site II. (Sup. by Chas. H. Hood Foundation

SEROLOGIC MARKERS OF HEPATITIS A (HAV) AND B (HBV) IN 393 BILIARY ATRESIA (BA) AND NEONATAL HEPATITIS (NH). William Balistreri, Edward Tabor, Jacques Drucker and Robert Gerety (Spon by P.Holtzapple) Univ. of Pa. Sch. , Dept. of Peds., Phila. and Bur. of Biol., FDA, Bethesda, Md. Med. Etiological speculation regarding BA and NH has implicated perinatal virus infection, however no consistent agent has been found. We sought serologic evidence of HAV or HBV infection in BA and NH by screening, at 2-6 months, 18 infant-mother pairs and 6 unpaired pts. Specific, sensitive radioimmunoassays (RIA) were used to test for HBV surface antigen (HBsAg) and antibody (anti-HBs); complement fixation for antibody to HBV core antigen (anti-HBc). Antibody to HAV (anti-HAV) was assayed by RIA, as well as the less sensitive immune adherence assay (IAHA). # tested HBsAg(+) anti-HBs(+) anti-HBc(+) anti-HAV(+) BA infants 16 0 0 0 2 0 IÀHÁ mothers 14 8 0 0 00 0 6\* NH infants NH infants o o o o o 2\* 2 mothers 4 0 0 0 2\* 2 \*= anti-HAV(+) found in 20-45% of USA women of childbearing age There was no evidence of active or past HBV infection. Both BA infants with detectable anti-HAV were born to anti-HAV(+) mo-thers; serial testing in one revealed declining titers, suggest-ing transplacental transfer. Of 3 anti-HAV(+) NH infants, mater-nal antibody was present in one; serial titers showed disappear-ance by 7 mos. Maternal serum was not available in the remaining two Thus it is unlikely that aithor HAV or HBV had an etiologic two. Thus, it is unlikely that either HAV or HBV had an etiologic role in BA or NH. A non-viral etiology or other non-A,non-B hepa titis viruses must be considered when assays become available.

SERUM SULFATED (S) AND NONSULFATED (NS) BILE ACID (BA) CONCENTRATION VIA DUAL-BEAM SPECTROPHOTOFLUORI-METRY (DBSF). <u>William F. Balistreri</u>, Marcelle J. 394 Shapiro and Roger D. Soloway (Spon. by P.G. Holtzapple) Univ. of ennsylvania, School of Med., Depts. of Peds. and Med., Phila., Pa The concentration and fluctuation of BA in serum may be the most sensitive index of hepatic dysfunction. Of existing methods gas-liquid chromatography (GC) is complex and radioimmunoassay (RIA) is limited by availability of specific antibodies. We have modified the DBSF method (Siskos, et.al.,J Lipid Res 18:666,'77) to measure NS+S BA by differences in fluorescence (f) between sample and reference cuvettes. Paired extraction with 1) isopropanol-reduces f due to protein, and with 2) ethanol/acetonecauses solvolysis, allowing enzymatic oxidation at 3¢ -position. Total solvolysis, allowing enzymatic oxidation at 54 - position. Total solvolysis of standards was confirmed by TLC. Recovery of 14C-taurocholate was >92%. BA concentration by DBSF correlated with GC (r=0.97) and with RIA for cholylglycine (r=0.91). Normal fasting total BA (8.6+2.5 SD µmol/1) was followed by a postprandial (90') two-fold increase due to influx via the enterohepatic circulation. No overlap with normals was found in acute (27 +10.5 or chronic (79+43) hepatitis. There were no significant differen ces in values obtained at comparable ages in 9 patients with neo natal hepatitis (105+51) and 16 patients with biliary atresia (132+61). S comprised a varying percentage of total BA, being virtually absent (2-5%) in normals, increasing to 15-25% with severe cholestasis. CONCLUSION: A valid modified DBSF assay for S+NS, which is reproducible, rapid and easily performed on 0.1ml of serum may be a sensitive screen for liver disease.

| RECURRENT ABDOMINAL PAIN (RAP) OF CHILDHOOD DUE TO   |  |  |  |
|--|--|--|--|
| 395 LACTOSE INTOLERANCE: A PROSPECTIVE STUDY. R.G. Barr,                                   |  |  |  |
| J.B. Watkins, and M.D. Levine. Harvard Med. School,  |  |  |  |
| Children's Hosp. Med. Ctr., Boston, Mass.  |  |  |  |
| The role of lactose intolerance was assessed prospectively in                              |  |  |  |
| 47 consecutive children (4.2-15 yrs: mean 9.5)presenting as out-                           |  |  |  |
| patients with RAP. Milk ingestion and pain frequency (documented                           |  |  |  |
| by diary) and symptom production following lactose ingestion (2gm                          |  |  |  |
| kg; max. 50 gm) were correlated with lactose malabsorption deter-                          |  |  |  |
| mined by breath hydrogen excretion (> 10 parts per million above                           |  |  |  |
| baseline) - an accurate technique for demonstrating disaccharide                           |  |  |  |
| malabsorption in children(Perman, JA et al, Ped. Res. 11:488,                              |  |  |  |
| 1977). Lactose malabsorbers underwent a 3-stage elimination diet                           |  |  |  |
| including a regular diet control period. There were no differ-                             |  |  |  |
| ences between lactose malabsorbers and absorbers with regard to                            |  |  |  |
| amount of milk ingested (1.6 vs 1.7 glasses/day; p>0.5) or pain                            |  |  |  |
| frequency (11.7 vs 8.4 episodes/week; p>0.5). Lactose malabsorp-                           |  |  |  |
| tion occurred in 20 children(43%), 9/34 were Caucasian, 8/11                               |  |  |  |
| Black and 2/2 Hispanic. Cramps or diarrhea were reported in 82%                            |  |  |  |
| of malabsorbers and 41% of absorbers. 11 of 20 malabsorbers have                           |  |  |  |
| completed the diet trial; in 10 of 11 pts., pain frequency was                             |  |  |  |
| reduced (paired t test; n=8; p<0.05): 3 patients refused to con-                           |  |  |  |
| tinue the control diet due to symptoms. Conclusion: In RAP, lac-                           |  |  |  |
| tose malabsorption is present and significantly contributes to                             |  |  |  |
| symptoms in at least 1 in 4 pts, regardless of ethnic background.                          |  |  |  |
| Milk ingestion, pain frequency and symptom response to lactose                             |  |  |  |
| are unreliable indicators of lactose malabsorption. Thus, docu-                            |  |  |  |
| mentation of lactose malabsorption is indicated in children with recurrent abdominal pain. |  |  |  |

| TOTAL PARENTERAL NUTRITION (TPN) CHOLESTASIS IN PRE-  |
|---|
| <b>396</b> TOTAL PARENTERAL NUTRITION (TPN) CHOLESTASIS IN PRE-<br>MATURE INFANTS. Ernest F. Beale, Robert M. Nelson, |
| Richard   Rucciarelli, William H. Uonnelly, Donald V.   |
| Fitzman, University of Florida College of Medicine, Shands Teach-   |
| ing Hospital Dept of Ped, and Path., Gainesville,   |
| Of the 221 infants admitted in 1976 weighing <2000 gm, 33% re-  |
| ceived TPN for periods ranging from 1 to 111 days. Of these 1n-   |
| fants receiving TPN 25% (16) developed direct hyperbilirubinemia  |
| $(\geq 1.5 \text{ mg}^{\alpha})$ secondary to TPN cholestasis. The onset of direct                                    |
| hyperbilirubinemia occurred at a mean of 40 days but varied from  |
| the end of the 1st week to the 13th week of TPN, without any ap-  |
| parent time of peak incidence. The incidence of TPN cholestasis   |
| was 8.8% in infants receiving TPN for 10 days and increased pro-  |
| gressively to 47% at 40 days. The highest incidence of direct   |
| hyperbilizubinemia was found in the very premature infant. Inc.   |
| incidence in the <1000 gm group was 53%. The incidences in the  |
| 11000-1499 am and 1500-2000 am groups were 18% and 12% respective   |
| ly Comparing the means for hirth weights. length of IPN, and  |
| protein intakes in the infants with and without elevated direct   |
| bilinubing novealed the following data: 101AL AVERAGE   |
| Direct Bilirubin <1.5 $1000000000000000000000000000000000000$   |
| Direct Bilirubin <1.5 75.4% 1332 14 31 1.9  |
| Direct Bilirubin $\geq 1.5$ 24.6% 1098 53 115 2.2   |
| It appears that very low birth weight infants are particularly  |
| susceptible to TPN cholestasis but this is probably due to the  |
| fact that they required TPN for longer periods of time. The   |
| length of TPN and the total amount of protein administered were   |
| the greatest risk factors in the production of TPN cholestasis.   |
| 1   |